ERBB2 and non-small cell lung carcinoma: The DESTINY‐Lung 01 and DESTINY‐Lung 02 studies showed that DS‐8201 resulted in a mPFS of 8.2 months and a mOS of 17.8 months in the later‐line treatment of HER2‐mutated NSCLC and was subsequently approved by the US Food and Drug Administration as a standard treatment option [7, 8].